title: Abatacept as an option therapy in difficult to treat psoriatic arthritis.
abstract: Psoriatic arthritis (PA) is an inflammatory arthritis associated with cutaneous psoriasis. Treatment consists of non-steroidal anti-inflammatory drugs, corticosteroids at low doses and disease-modifying anti-rheumatic drugs. We relate a case of PA that after the fault of the handlings convecionais to sick we opted for an empiric treatment with Abatacept, based on the current knowledge on the physiopathology of PA and its low hepatotoxicity found in an animal model.
authors: Francisco José Fernandes
authors: FJ
authors: Vieira
authors: Maria Roseli Monteiro
authors: MR
authors: Callado
authors: Walber Pinto
authors: WP
authors: Vieira
mesh_terms: D000069594:Abatacept; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D006505:Hepatitis / Q000209:etiology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007538:Isoniazid / Q000009:adverse effects; D007555:Isoxazoles / Q000627:therapeutic use; D007596:Joints / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D000077339:Leflunomide; D007866:Leg / Q000473:pathology / Q000503:physiopathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D019384:Nucleic Acid Synthesis Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept; D000077339:Leflunomide; D007538:Isoniazid; D008727:Methotrexate